Trevena Inc. (NASDAQ:TRVN)’s share price was up 1.8% on Friday . The stock traded as high as $6.79 and last traded at $6.71, with a volume of 373,255 shares traded. The stock had previously closed at $6.59.

Several research firms recently issued reports on TRVN. FBR & Co restated a “buy” rating and set a $16.00 price objective on shares of Trevena in a research report on Wednesday, May 4th. Needham & Company LLC restated a “buy” rating on shares of Trevena in a research report on Tuesday, May 3rd. Brean Capital restated a “buy” rating on shares of Trevena in a research report on Tuesday, May 3rd. Finally, Cowen and Company restated a “buy” rating on shares of Trevena in a research report on Tuesday, May 3rd. Two investment analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $14.70.

The company’s 50-day moving average is $6.79 and its 200-day moving average is $7.77. The firm’s market capitalization is $350.09 million.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.03. On average, equities research analysts expect that Trevena Inc. will post ($1.29) EPS for the current year.

In other Trevena news, CEO Maxine Gowen acquired 22,084 shares of the firm’s stock in a transaction that occurred on Friday, May 27th. The shares were acquired at an average cost of $7.12 per share, for a total transaction of $157,238.08. Following the transaction, the chief executive officer now directly owns 279,025 shares of the company’s stock, valued at $1,986,658. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Other large investors have added to or reduced their stakes in the company. AWM Investment Company Inc. acquired a new stake in Trevena during the fourth quarter valued at approximately $2,100,000. Marshall Wace LLP acquired a new stake in Trevena during the fourth quarter valued at approximately $1,929,000. California State Teachers Retirement System raised its stake in Trevena by 77.9% in the fourth quarter. California State Teachers Retirement System now owns 103,238 shares of the biopharmaceutical company’s stock valued at $1,084,000 after buying an additional 45,212 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in Trevena by 0.3% in the fourth quarter. Jennison Associates LLC now owns 702,341 shares of the biopharmaceutical company’s stock valued at $7,375,000 after buying an additional 2,341 shares in the last quarter.

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.